Evolutionary Therapy for Rhabdomyosarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Rhabdomyosarcoma
Interventions
DRUG

Vincristine

IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg

DRUG

Cyclophosphamide

IV over 60 minutes with dosing ranging from 220mg to 1200mg

DRUG

Vinorelbine

IV push over 6-10 minutes with dosing ranging from 4mg-25mg

DRUG

Actinomycin D

Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg

DRUG

Cyclophosphamide Pill

Based on Body Surface Area (BSA) round to nearest 25mg

Trial Locations (18)

10467

RECRUITING

Montefiore Medical Cancer Center, The Bronx

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

27599

RECRUITING

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

27710

RECRUITING

Duke Children's Hospital, Durham

28204

RECRUITING

Carolinas Medical Center, Levine Cancer Institute, Charlotte

32610

RECRUITING

University of Florida, Gainesville

33136

RECRUITING

University of Miami - Sylvester Comprehensive Cancer Center, Miami

33612

RECRUITING

Moffitt Cancer Center, Tampa

33701

RECRUITING

Johns Hopkins All Children's Hospital, St. Petersburg

35294

RECRUITING

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

37232

RECRUITING

Vanderbilt - Ingram Cancer Center, Nashville

43205

RECRUITING

Nationwide Children's Hospital, Columbus

44106

RECRUITING

Cleveland Clinic, Cleveland

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

77030

RECRUITING

MD Anderson, Houston

80045

RECRUITING

Children's Hospital of Colorado, Aurora

84113

RECRUITING

Primary Children's Medical Center/Utah, Salt Lake City

06106

RECRUITING

Connecticut Children's Medical Center, Hartford

All Listed Sponsors
collaborator

National Pediatric Cancer Foundation

OTHER

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER